C-Rad AB (publ) (CRAD-B) - Total Liabilities

Latest as of December 2025: Skr153.60 Million SEK ≈ $16.53 Million USD

Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has total liabilities worth Skr153.60 Million SEK (≈ $16.53 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore C-Rad AB (publ) cash flow conversion to assess how effectively this company generates cash.

C-Rad AB (publ) - Total Liabilities Trend (2008–2025)

This chart illustrates how C-Rad AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are C-Rad AB (publ)'s assets to evaluate the company's liquid asset resilience ratio.

C-Rad AB (publ) Competitors by Total Liabilities

The table below lists competitors of C-Rad AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Airtasker Ltd
AU:ART
Australia AU$68.33 Million
IF Bancorp Inc
NASDAQ:IROQ
USA $743.01 Million
IMCO Industries Ltd
TA:IMCO
Israel ILA197.86 Million
Xtract One Technologies Inc.
TO:XTRA
Canada CA$13.36 Million
BEML LAND ASSETS LTD
NSE:BLAL
India Rs121.00 Million
Abcourt Mines Inc.
V:ABI
Canada CA$36.30 Million
Delfingen
PA:ALDEL
France €228.99 Million

Liability Composition Analysis (2008–2025)

This chart breaks down C-Rad AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CRAD-B company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.09 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.44 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how C-Rad AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for C-Rad AB (publ) (2008–2025)

The table below shows the annual total liabilities of C-Rad AB (publ) from 2008 to 2025.

Year Total Liabilities Change
2025-12-31 Skr153.60 Million
≈ $16.53 Million
-6.55%
2024-12-31 Skr164.37 Million
≈ $17.69 Million
+34.29%
2023-12-31 Skr122.40 Million
≈ $13.17 Million
+26.67%
2022-12-31 Skr96.63 Million
≈ $10.40 Million
+27.79%
2021-12-31 Skr75.62 Million
≈ $8.14 Million
+6.90%
2020-12-31 Skr70.73 Million
≈ $7.61 Million
-5.00%
2019-12-31 Skr74.46 Million
≈ $8.01 Million
+40.56%
2018-12-31 Skr52.97 Million
≈ $5.70 Million
+13.55%
2017-12-31 Skr46.65 Million
≈ $5.02 Million
+48.09%
2016-12-31 Skr31.50 Million
≈ $3.39 Million
-6.19%
2015-12-31 Skr33.58 Million
≈ $3.61 Million
+2.92%
2014-12-31 Skr32.63 Million
≈ $3.51 Million
+37.41%
2013-12-31 Skr23.74 Million
≈ $2.56 Million
+8.61%
2012-12-31 Skr21.86 Million
≈ $2.35 Million
+20.19%
2011-12-31 Skr18.19 Million
≈ $1.96 Million
-7.69%
2010-12-31 Skr19.70 Million
≈ $2.12 Million
+31.18%
2009-12-31 Skr15.02 Million
≈ $1.62 Million
+12.65%
2008-12-31 Skr13.33 Million
≈ $1.43 Million
--

About C-Rad AB (publ)

ST:CRAD-B Sweden Medical Devices
Market Cap
$86.08 Million
Skr799.87 Million SEK
Market Cap Rank
#19753 Global
#347 in Sweden
Share Price
Skr24.90
Change (1 day)
-0.80%
52-Week Range
Skr24.90 - Skr36.25
All Time High
Skr66.70
About

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more